Allopurinol, gout, and cardiovascular risk - Takeaways - MDSpire

Allopurinol, gout, and cardiovascular risk

  • By

  • Jalina Jannink

  • Arend Mosterd

  • Aernoud T L Fiolet

  • October 29, 2025

Share

  • 1

    Patients with gout face increased cardiovascular risks, potentially due to hyperuricaemia and oxidative stress.

  • 2

    The ALL-HEART trial found no cardiovascular benefit from high-dose allopurinol in patients without gout.

  • 3

    A Dutch study showed that ischaemic cardiovascular events increased significantly during the first 30 days of allopurinol initiation.

  • 4

    Higher starting doses of allopurinol (>300 mg) were associated with greater cardiovascular risk compared to lower doses.

  • 5

    Concomitant use of colchicine mitigated early cardiovascular risks associated with allopurinol treatment.

Original Source(s)

Allopurinol, gout, and cardiovascular risk

  • by Jalina Jannink, Arend Mosterd, Aernoud T L Fiolet

  • October 29, 2025

Related Content

Association between circulating biomarkers of endothelial glycocalyx degradation and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass

Mechanistic insights into lipoprotein(a)-induced cardiomyocyte ferroptosis via ROS/p38/p53 signaling

Cumulative triglyceride-glucose-body mass index exposure and cardiovascular disease risk: findings from the Kailuan study